BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Abaxis To Report Second Quarter Fiscal Year 2018 Financial Results On Tuesday, October 24, 2017

  Abaxis has scheduled a conference call to discuss its financial results for the second quarter fiscal year 2018, ended September 30, 2017.

  October 17, 2017

   · 

  1 min read
• Business

  Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017

  Mylan today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017, at 10:30 a.m. ET, to review the company’s financial results for the third quarter ended Sept. 30, 2017.

  October 17, 2017

   · 

  1 min read
• Business

  Menlo Therapeutics Expands its Management Team

  Menlo Therapeutics is developing a neurokinin 1 (NK1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment of refractory chronic cough.

  October 17, 2017

   · 

  4 min read
• Business

  Adventist Health System Partners With Glytec To Enhance Diabetes Care

  More than a quarter of all hospitalized patients in the U.S. have diabetes, and typically, these patients stay longer, experience more infections and have higher readmission rates.

  October 17, 2017

   · 

  5 min read
• Drug Development

  Chi-Med And Astrazeneca’s Savolitinib Shows Encouraging Clinical Activity In Second-Line EGFR Mutation-Positive Lung Cancer With MET-Amplification

  Hutchison China MediTech Limited and AstraZeneca PLC today presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso® (osimertinib) or Iressa® (gefitinib) in two Phase Ib/II proof-of-concept trials.

  October 17, 2017

   · 

  9 min read
• Business

  Forge & Evotec Expand Strategic Alliance With Launch Of BLACKSMITH Platform To Discover Novel Metalloenzyme Inhibitors Across Broad Therapeutic Areas

  Forge announced today that the companies have expanded their existing strategic alliance and launched the BLACKSMITH platform to discover a broader range of therapeutics targeting metalloenzymes.

  October 17, 2017

   · 

  4 min read
• Business

  BrainStorm Announces Third Quarter 2017 Financial Results

  BrainStorm announced financial results for the third quarter ending September 30, 2017.

  October 17, 2017

   · 

  14 min read
• Business

  Cadent Therapeutics Receives Milestone for the Initiation of Phase I Clinical Studies

  Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of a Phase 1 clinical study of a subtype selective NMDA receptor NAM for the treatment of treatment-resistant depression.

  October 17, 2017

   · 

  1 min read
• Genetown

  Syndax Announces $25 Million Registered Direct Offering of Common Stock

  Syndax today announced that it has agreed to sell 2,021,018 shares of its common stock to BVF in a registered direct offering.

  October 17, 2017

   · 

  4 min read
• BioMidwest

  Southern Spine Announces “Clinical and Biomechanical Advantages of Interspinous Process Fixation: A Review”

  Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced today the release of a current literature review on the “Clinical and Biomechanical Advantages of Interspinous Process Fixation.”

  October 17, 2017

   · 

  2 min read